Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Once Daily Etravirine versus Efavirenz in Treatment-Naive
SENSE: Study Design

<table>
<thead>
<tr>
<th>Study Design: SENSE Study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Background</strong>: Randomized, controlled, double-blind, phase 2 trial evaluating efficacy of once-daily etravirine compared with efavirenz in treatment-naïve persons with HIV</td>
</tr>
<tr>
<td><strong>Inclusion Criteria (n = 157)</strong></td>
</tr>
<tr>
<td>- Age ≥18 years</td>
</tr>
<tr>
<td>- Antiretroviral-naïve</td>
</tr>
<tr>
<td>- HIV RNA &gt;5000 copies/mL</td>
</tr>
<tr>
<td>- No resistance to study drugs</td>
</tr>
<tr>
<td><strong>Treatment Arms</strong></td>
</tr>
<tr>
<td>- ETR 400 mg daily + 2NRTIs*</td>
</tr>
<tr>
<td>- Efavirenz 600 mg daily + 2NRTIs*</td>
</tr>
<tr>
<td>*NRTIs = tenofovir DF-emtricitabine, abacavir, lamivudine, or zidovudine-lamivudine</td>
</tr>
</tbody>
</table>

**SENSE** = **Study of Efavirenz Neuropsychiatric events versus Etravirine**


**SENSE** Study Design:
- **ETR 400 mg once daily** + 2 NRTIs (n = 79)
- **Efavirenz 600 mg once daily** + 2 NRTIs (n = 78)
Once Daily Etravirine *versus* Efavirenz

SENSE: Results

Week 48: Virologic Response (ITT-TLOVR*)

![Bar chart showing virologic response at Week 48 for Etravirine and Efavirenz arms, stratified by baseline HIV RNA level.](chart.png)

**HIV RNA <50 copies/mL (%)**

- **All**
  - Etravirine Arm: 60/79 (76%)
  - Efavirenz Arm: 58/78 (74%)

- **≤100,000 copies/mL**
  - Etravirine Arm: 40/52 (77%)
  - Efavirenz Arm: 40/51 (78%)

- **>100,000 copies/mL**
  - Etravirine Arm: 20/27 (74%)
  - Efavirenz Arm: 18/27 (67%)

*ITT-TLOVR = Intention to Treat-Time to Loss of Virologic Response*

Once Daily Etravirine *versus* Efavirenz

**SENSE: Result**

**Conclusion**: “First-line treatment with etravirine 400mg once daily and two nucleoside reverse transcriptase inhibitors (NRTIs) led to similar rates of HIV RNA suppression, compared with efavirenz and two NRTIs. None of the patients with virological failure in the etravirine arm developed resistance to nonnucleosides.”

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.